The medical community is moving away from the "one-size-fits-all" approach of systemic chemotherapy, placing the Antibody Drug Conjugate Market at the forefront of modern precision medicine. By utilizing a "lock and key" mechanism, ADCs ensure that toxic payloads are only released once they reach the tumor site, minimizing collateral damage to healthy tissues.

This level of selectivity is a primary driver for the US Antibody Drug Conjugate Market, where patients and providers are increasingly demanding treatments that offer a higher quality of life. Unlike traditional drugs, ADCs use sophisticated linkers that remain stable in the bloodstream, only breaking down in the presence of specific enzymes found within cancer cells. This innovation has led to the development of drugs like Enhertu, which has shown unprecedented success in treating HER2-low breast cancer, a segment previously underserved by targeted therapies.